OBJECTIVES: Multiple Sclerosis (MS) is a chronic neurological disease affecting the central nervous system with a prevalence rate of 240 per 100,000 in Canada. The prevalence of pain in MS ranges from 10%-80% (70% in a study we previously performed). Sativex® (SAT) is a new cannabis-based drug approved in Canada for neuropathic pain in patients with MS. Willingness-to-pay (WTP) elicits the extent of subjects' preference for their chosen treatment, expressed as the amount they would hypothetically be willing to pay in insurance premiums in order to have access to the treatment. METHODS: The WTP instrument had a decision board (DB) and a questionnaire. A DB is a visual aid to help clinicians present clinical information about treatment options in a standardized manner. Two treatment options were presented on the board used in this study, with text and data describing them obtained from clinical experts and the literature. The first option was a “cocktail” of three medications: gabapentin, amytriptylin, and acetaminophen (“pills”), while the comparator was the same “cocktail” but adding SAT (“pills and oral spray”). The WTP instrument was administered to 500 participants from the general Canadian population, using the bidding game approach. Descriptive statistics were calculated. RESULTS: The mean age of the study population was 39 ±13 years, 56% were female. The DB was facilitated in English (85%) and French (15%). Of the 500 interviews conducted, 253 respondents chose the “pills and oral spray” option. For these subjects, the mean WTP per month in additional insurance premium was CAD $8 (range= $0-$200, median= $4). CONCLUSION: Assuming only 51% in a general population are willing to pay additional premiums as reported, the obtained WTP would be able to fund the drug for all MS patients with pain (assumed 70%), with a remaining surplus of $3.24/person.